[Spondyloarthritis: modern terminology and definitions].

Aim to identify outdated terms and make changes to the terminology of spondyloarthritis. MATERIALS AND METHODS: At the first stage of the work, the terms divided into two categories: "outdated" definitions and terms that need to be improved or unified. Subsequently, each member of the Expert Group of Spondyloarthritis at the Association of Rheumatologists of Russia (ExSpA) presented by its own definition of the designated term or agreed with the previous term. At the next stage, the existing definitions were put together. After discussion, experts left a term that scored at least 2/3 of the votes. The special opinion of experts was recorded, whose did not coincide with the majority opinion. An open vote was conducted, when defining an "outdated" term with the unanimous decision of all group members, this term was not recommended for further clinical use. RESULTS: The work carried out allowed us to identify a number of terms that are not recommended for use in clinical practice. Number of terms are defined, which should be used when discussing the problem of spondyloarthritis. CONCLUSION: The Expert Group of Spondyloarthritis at the Association of Rheumatologists of Russia suggests using or, accordingly, not using a number of terms and their definitions in clinical practice.

[Cardiovascular risk in psoriatic arthritis].

AIM: To evaluate cardiovascular risk in psoriatic arthritis (PA). MATERIAL AND METHODS: The examination covered 61 PA patients (52.9% females) aged 30-55 years and 45 controls without inflammatory and degeneratory diseases matched by gender, age and body mass. Standard cardiovascular risk factors were analysed. C-reactive protein was measured with a highly sensitive method. Carotid arteries were subjected to duplex scanning. RESULTS: PA patients had a high cardiovascular risk. Dyslipidemia manifested with a high total cholesterol, LDLP cholesterol which correlated with inflammation activity. PA was more frequently associated with subclinical atherosclerosis and atherosclerotic plaques. CONCLUSION: Chronic immune inflammation underlying pathogenesis of PA contributes to development of early atherosclerosis and its complications. A high cardiovascular risk is a constituent of PA which had an impact on long-term prognosis of this disease.

[The heart damage in patients with psoriatic arthritis]. / Porazhenie serdtsa u bol'nykh psoriaticheskim artritom.

AIM: To examine the rate and features of heart damage in psoriatic arthritis (PA) patients and find out whether some parameters of PA are associated with cardiac involvement. MATERIAL AND METHODS: The study enrolled 370 PA patients aged 15 to 72 years with the disease history 1 to 44 years having different variants of the articular and skin syndromes. The patients have undergone various tests including chest x-ray, ECG, echocardiography. RESULTS: Myocarditis, adhesive pericarditis, valvular defects (mitral, aortic and combined mitral-aortic were diagnosed in 15.9, 18.2 and 5.7% of PA patients, respectively). Aortitis was detected in 51.3% patients with advanced sacroileitis and alkylosing spondylarthritis. Alterations in the heart were associated with spinal lesions, other systemic manifestations, activity of the disease and, in a lesser degree, with carriage of HLA-B27. CONCLUSION: Cardiac syndrome in PA is characterized by marked heterogeneity and is one of basic systemic manifestations of this disease. Latent PA aortatis can be detected at echocardiography.

[A multicenter evaluation of efficacy and tolerance in the local treatment with dolgit cream of patients with osteoarthrosis]. / Mnogotsentrovaia otsena éffektivnosti i perenosimosti lokal'noi terapii kremom dolgit u bol'nykh osteoartrozom.

A 2-week clinical trial of cream dolgit efficacy and tolerance in 76 patients with primary osteoarthritis in 8 rheumatological centers showed this preparation to reduce local pain syndrome in 70.1%, palpation pain sensitivity in 79.2%, joint swelling in 75.5% of patients. Unwanted reactions in the form of skin itch at the site of application were reported in 7.8% of cases.

[Nimesil effectiveness in rheumatoid arthritis]. / Effektivnost' nimesila pri revmatoidnom artrite.

Clinical efficiency and safety of nimesil were studied in the multicenter open clinical trial of 52 patients with verified rheumatoid arthritis. Nimesil was given for 12 weeks in a daily dose 200-400 mg in addition to basic therapy. Clinical and laboratory parameters were assessed after 4 and 8 weeks of the treatment and after its end. The treatment produced a significant positive response of the articular syndrome. Marked improvement was registered in 11 (23.4%) patients, improvement--in 33 (79.2%) patients. Side effects were reversible and occurred in 8 (15.3%) patients. In 5 patients the drug was withdrawn. The conclusion is made on high efficiency and good tolerance of nimesil in rheumatoid arthritis patients.

[The metabolism of the main substance of connective tissue and of collagen proteins in psoriasis patients]. / Metabolizm osnovnogo veshchestva soedinitel'noi tkani i kollagenovykh belkov u bol'nykh psoriazom.

Blood and serum glucosaminoglycanes, serum glycosaminoglycane hydrolases, hydroxyprolinuria were measured in 140 patients, 60 of these suffering from psoriasis and 80 from psoriatic arthropathy. A relationship between the severity of impairments of connective tissue metabolism and dissemination of the skin process, as well as activity of articular and visceral inflammations, was examined. The detected regularities are discussed in the light of psoriasis pathogenesis; differential diagnostic potentialities of these regularities are analyzed.